Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Prescription Generic Deal
Dr. Reddy's Seeks Gaining Foothold In Women's Health Via Mayne Pharma's U.S. Prescription Generic Deal
雷迪博士寻求通过梅恩制药的美国处方仿制药协议在女性健康领域站稳脚跟
- Dr. Reddy's Laboratories Ltd (NYSE:RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC:MAYND) (OTC:MAYNF) (OTC:MYPHY).
- Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approximately $90 million in cash, with contingent payments of up to $15 million.
- Consideration towards inventory and credits for certain accrued channel liabilities are to be determined on the closing date.
- The portfolio includes approximately 45 commercial, four pipeline, and 40 approved non-marketed products, including several generic products focused on women's health.
- For FY ended June 30, 2022, Mayne Pharma reported total revenue of $111 million for the acquired portfolio.
- Approved products include a hormonal vaginal ring, a birth control pill, and a cardiovascular product.
- The acquisition will complement Dr. Reddy's U.S. retail prescription pharmaceutical business with limited competition products.
- Marc Kikuchi, CEO, North America business, Dr. Reddy's, said, "This important acquisition provides our North America organization with a significant foothold in the women's health space."
- Erez Israeli, CEO, Dr. Reddy's, said, "The U.S. has always been an important market for us. The portfolio of products acquired from Mayne Pharma is a strategic fit with our growth objectives. The portfolio includes some high entry-barrier products. It also complements our existing portfolio by introducing products focused on women's health."
- Price Action: RDY shares traded lower by 0.29% at $54.01 on the last check Monday.
- 雷迪博士实验室有限公司(纽约证券交易所股票代码：RDY)已同意收购澳大利亚的美国仿制药产品组合美恩医药集团有限公司(场外交易：MAYND)(场外交易：MAYNF)(场外交易：MYPHY)
- 根据协议条款，雷迪博士将以大约9000万美元的现金预付款收购该投资组合，或有付款最高可达1500万美元。
- 对某些应计渠道负债的存货和信用的对价将在结算日确定。
- 该产品组合包括大约45种商业产品、4种流水线产品和40种已批准的非上市产品，其中包括几种侧重于妇女健康的仿制药。
- 在截至2022年6月30日的财年，梅恩制药公司报告收购的投资组合的总收入为1.11亿美元。
- 批准的产品包括荷尔蒙阴道环、避孕药和心血管产品。
- 此次收购将补充Dr.Reddy的美国零售处方药业务，提供竞争有限的产品。
- Reddy‘s公司北美业务首席执行官马克·菊池说：“这项重要的收购为我们的北美公司在妇女健康领域提供了一个重要的立足点。”
- Reddy‘s公司首席执行官埃雷兹·伊斯雷尔说：“美国一直是我们的一个重要市场。从Mayne Pharma收购的产品组合符合我们的增长目标。该产品组合包括一些进入门槛较高的产品。它还通过推出专注于女性健康的产品来补充我们现有的产品组合。”
- 价格行动：在周一的最后一次检查中，Rdy的股价下跌了0.29%，至54.01美元。